Lilly Oncology to Welcome Aboard New VP of Late Phase Development, Maura Dickler

Maura Dickler, MD

Maura Dickler, MD

Lilly Oncology has hired Maura Dickler, MD, to serve as vice president of late phase development, beginning May 7, 2018. She will report to Levi Garraway, MD, PhD, senior vice president of global development and medical affairs of Lilly Oncology.

Known for her prestigious breast cancer research, Dickler’s accomplishments have led her to countless publications and honors. She has been named one ofNew York Magazine’sBest Doctors in Medical Oncology in 2015, 2016, and 2017. She has also been named one of Castle Connolly America’s Top Doctors, and Castle Connolly Exceptional Women in Medicine in 2017.

Since graduating from The University of Chicago’s Pritzker School of Medicine with a fellowship at Memorial Sloan Kettering Cancer Center (MSKCC), Dickler has led numerous clinical trials with a focus on development of therapeutic strategies for treatment of patients with hormone-receptor—positive (HR+) breast cancer.

Some of her trials investigated therapeutic agents targeting growth factor receptor signaling pathways. These pathways include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (VEGFR), phosphoinositide 3-kinase (PI3K), and the estrogen receptor pathway. Her studies have also looked at cyclin-dependent kinase 4 & 6 (CDK4&6) inhibitors that target the cell cycle.

Dickler currently serves as section head of the Endocrine Therapy Clinical Research Program at MSKCC. She is also an associate member of the Breast Medicine Service in the Department of Medicine at MSKCC and associate professor of medicine at Weill Cornell Medical College, New York.

“Dr Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities. Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does,” said Garraway in a statement.